(NASDAQ: BCRX) Biocryst Pharmaceuticals's forecast annual revenue growth rate of -0.2% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.33%.
Biocryst Pharmaceuticals's revenue in 2026 is $885,716,000.On average, 11 Wall Street analysts forecast BCRX's revenue for 2026 to be $173,031,397,301, with the lowest BCRX revenue forecast at $157,293,645,394, and the highest BCRX revenue forecast at $195,473,960,179. On average, 11 Wall Street analysts forecast BCRX's revenue for 2027 to be $188,202,366,477, with the lowest BCRX revenue forecast at $168,352,262,731, and the highest BCRX revenue forecast at $207,045,986,089.
In 2028, BCRX is forecast to generate $223,790,222,130 in revenue, with the lowest revenue forecast at $177,031,917,570 and the highest revenue forecast at $257,720,937,240.